| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Published online before print February 24, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Medicine and Microbiology–Immunology, University of California, San Francisco
1Correspondence: Departments of Medicine and Microbiology–Immunology, University of California, 533 Parnassus Ave., Room UB8B, San Francisco, CA 94143-0711. E-mail: egoetzl{at}itsa.ucsf.edu
The lysophospholipid (LPL) growth factors sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) are generated by macrophages, dendritic cells, mast cells, and platelets, which leads to lymph and plasma concentrations of 0.1–1 µM. Distinctive profiles of G protein-coupled receptors (GPCRs) for S1P and LPA are expressed by each type of immune cell and are regulated by cellular activation. At 1–100 nM, S1P signals T cells through their principal S1P1 GPCRs with consequent protection from apoptosis, enhancement of chemotaxis, and facilitation of optimal regulatory activity of CD4+25+ T cells. At 0.3–3 µM, S1P inhibits T cell chemotaxis and to a lesser extent other functions. These S1P–S1P1 GPCR signals suppress homing of blood and spleen T cells to secondary lymphoid tissues. S1P1 GPCR antagonists evoke lymphopenia by permitting blood T cells to enter lymph nodes and blocking S1P1 GPCR-dependent T cell efflux from lymph nodes. Inversely, there is a decrease in lymphoid tissue traffic of T cells in transgenic mice, which overexpress lymphocyte S1P1 GPCRs. The immunotherapeutic activity of S1P1 GPCR antagonists, which limits T cell access to organ grafts and autoimmune antigens, does not reduce other functional capabilities of T cells. LPLs and their GPCRs thus constitute an immunoregulatory system of sufficient prominence for pharmacological targeting in transplantation, autoimmunity, and immunodeficiency.
Key Words: lysophospholipids • immunity • chemotaxis • FTY720
This article has been cited by other articles:
|
|
 |
|
  M. V. Shah, R. Zhang, R. Irby, R. Kothapalli, X. Liu, T. Arrington, B. Frank, N. H. Lee, and T. P. Loughran Jr Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes Blood, August 1, 2008; 112(3): 770 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Whetzel, D. T. Bolick, S. Srinivasan, T. L. Macdonald, M. A. Morris, K. Ley, and C. C. Hedrick Sphingosine-1 Phosphate Prevents Monocyte/Endothelial Interactions in Type 1 Diabetic NOD Mice Through Activation of the S1P1 Receptor Circ. Res., September 29, 2006; 99(7): 731 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Chalfant and S. Spiegel Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling J. Cell Sci., October 15, 2005; 118(20): 4605 - 4612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Jolly, M. Bektas, K. R. Watterson, H. Sankala, S. G. Payne, S. Milstien, and S. Spiegel Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors Blood, June 15, 2005; 105(12): 4736 - 4742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chi and R. A. Flavell Cutting Edge: Regulation of T Cell Trafficking and Primary Immune Responses by Sphingosine 1-Phosphate Receptor 1 J. Immunol., March 1, 2005; 174(5): 2485 - 2488. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
